ARS-Patent protected Novo Nordisk A/S’s interests in a patent dispute

ARS-Patent represented the interests of Novo Nordisk A/S in the patent dispute over the Rospatent’s decision on extension of the validity term of a patent related to Insulin degludec owned by Novo Nordisk A/S. Recently, a request of the plaintiff (Geropharm LLC) for the cassation appeal to be considered by the Court Board of the Supreme Court of the Russian Federation was rejected. That was the final step of the case.

During the legal proceedings, Kirill Osipov, the Head of Legal Department, being the authorized representative of the patentee showed the Court for Intellectual Property Rights, which considered Geropharm’s lawsuit as the first-instance court, that the term for filing such lawsuit as set by Russian law was missed by the plaintiff. In view of arguments and pieces of evidence provided, the Court rejected the lawsuit. The Court’s decision was also upheld by further court instances.

The case was widely discussed in the mass-media.

Make an enquiry

Latest News

Reimbursement of expenses when considering the disputes in Rospatent

2024-02-21

In accordance with the new Federal Law No. 390361-8 of January 30, 2024, with proposed amendments to Article 1248 of the Civil Code of the Russian Fed...

Read more
Amendments and addenda to the Patent Regulations under the EAPC

2024-01-12

As of January 1, 2024, amendments and addenda to Part I «Inventions» and Part II «Industrial Designs» of the Patent Regulations to the Eurasian Pa...

Read more

View all our News

MEET WITH US

Meet ARS-Patent at the 2023 AIPPI World Congress

2023-09-26

The 2023 AIPPI World Congress will bring together up to 2000 intellectual property professionals from around the world for a prestigious event, which ...

Read more
2023 IPO Annual Meeting

2023-08-16

We are glad to announce that Pavel Vorobev, the Client Manager and Patent Attorney of ARS-Patent, will attend the 2023 Intellectual Property Owners As...

Read more

See all Events

Back top